TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be more than 1 month old.~2. Have a history of culture positive fungal corneal ulcer, that began within 14 days of presentation to the study center characterized by either a stromal defect with infiltrate or exudate, or a positive fungal stain on smear. Other clinical criteria to suspect fungal ulcers include firm (sometimes dry) elevated slough, hyphate lines extending beyond the ulcer edge into normal cornea, endothelial plaque, history of organic material striking the eye, intense inflammation of the cornea and anterior chamber, immune ring, Descemet's folds, multifocal granular (or feathery) grey-white satellite stromal infiltrates. A hypopyon may be present. The diameter of the ulcer will be between 1 mm and 6 mm, as long as there is no scleral involvement.~3. It is acceptable to enroll a subject who has received a graft, provided the graft meets the following requirements:~   1. The central ulcer is well within the donor cornea.~  2. There is no suture abscess.~  3. The graft has not previously failed.~4. The subject should not have a foreign body present on or in the cornea or eye. A subject can be enrolled after the foreign body is totally removed and the other enrollment criteria are met.~Exclusion Criteria:~1. The initial culture fails to show the presence of fungi.~2. The patient has a history of allergy to povidone-iodine, iodine, or natamycin.~3. The cornea or sclera has been perforated or perforation is impending.~4. The unaffected eye is legally blind.~5. Dacrocystitis is present.~6. Neurotrophic keratitis, exposure keratitis or keratitis sicca is present.~7. Prescribed topical or systemic steroids or other immunosuppressants are being used, unless discontinued before randomization.~8. The patient is known to be HIV positive.~9. The infiltrate extends into the posterior one-third of the stroma.~10. The initial culture shows significant growth of bacteria (\>10 colonies).~11. Any topical antifungal agent has been used within the past week.~12. Both eyes are infected.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I: (Type: EXPERIMENTAL): povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
- II (Type: ACTIVE_COMPARATOR): natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fampridine Pregnancy Exposure Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Documentation that the patient was exposed to prolonged-release fampridine since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy. (If exposure dates are unknown, the reporter must be able to specify or estimate trimester of exposure.)~* The outcome of the pregnancy must not be known at the time of report.~Key Exclusion Criteria:~* None~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MDS by standard criteria. Patients within each of the FAB diagnostic groups of RA, RARS, RAEB, RAEBt, and CMML are eligible. For patients with lower-risk MDS only: documented red blood cell dependence, defined as the inability to maintain a hematocrit of \> 25% without transfusion support.~* Adequate marrow iron stores~* In patients with serum erythropoietin less than 200 IU/mL at screening, failure to have responded to a 2 to 3 month trial of recombinant erythropoietin~* Serum creatinine or serum bilirubin \< 1.5 times the upper limit of normal; higher levels are acceptable if ALT levels \< 2 x upper limits of normal~* Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine/treatment.~* Women of childbearing potential should be advised to avoid becoming pregnant and should be advised to not father a child while receiving treatment with azacitidine~* Age \> 18 years~Exclusion Criteria:~* Treatment with growth factors within the 30 days before first treatment with ATO/Azacitidine, except that patients with serum erythropoietin \< 200 IU/mL who failed to respond to a trial with EPO are not excluded regardless of the time since last EPO~* Treatment with cytotoxic or experimental agents within 30 days before first treatment with ATO/Azacitidine~* Absolute QT interval \> 460 msec in the presence of adequate serum potassium and magnesium values~* Active serious infections that are not controlled by antibiotics~* Pregnant or lactating women~* Inability or unwillingness to comply with the treatment protocol, follow-up, or research tests~* NYHA Class III or IV heart failure~* Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): see description in intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ventricular Assist Device (VAD) Research Registry and Blood Sub-Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is ≥ 18 years of age~2. Subject is treated with a VAD at the Butterworth Campus, Spectrum Health.~Exclusion Criteria:~1. Subject is less than 18 years of age.~2. Known prisoners of the state.~3. Subject is pregnant.~4. Non- English speaking patients will be excluded from the blood sub-study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Wellness Engagement Project, Petersburg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-65 years.~* Must have a school going child between 12-17 living in the home.~* BMI between 25 and 50 kg/m2.~Exclusion Criteria:~* report not being able to walk 2 blocks (1/4 mile) without stopping~* currently participating in another weight loss program~* taking a weight loss medication~* have a history of bariatric surgery~* pregnant or plan to become pregnant during the intervention timeframe~* report an unsupervised heart condition, chest pain during periods of rest or activity, or loss of consciousness on the Physical Activity Readiness Questionnaire~* report a medical condition that would jeopardize their safety if involved in a weight management program with diet and exercise guidelines (e.g., uncontrolled heart problem)~* fail medical screening by study medical staff)~* report conditions that, in the judgment of the PI, would render the participant unlikely to follow the study protocol (e.g., planned move from the area, dementia, substance abuse).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Intervention-Wellness Engagement Program (Type: EXPERIMENTAL): The group assigned to the intervention arm will receive treatment as described below for a twelve week period:~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events
- Delayed treatment control group (Type: NO_INTERVENTION): The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children undergoing cardiac catheterization who will have normal (non-shunted) physiology at the conclusion of the procedure.~Exclusion Criteria:~* Patients with additional congenital heart abnormalities, cardiac arrhythmias, ventricular dysfunction, and known pulmonary disease.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Cardiac catheterization (Type: None): Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hepatic Impairment Study for Lorlatinib in Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective;~* Biliary obstruction with a biliary drain or stent;~* Neurologically stable gliomas and brain metastases;~* ECOG performance status of 0, 1, or 2;~* adequate bone marrow function;~* adequate pancreatic function;~* adequate renal function;~* female patients with negative pregnancy test~Exclusion Criteria:~* untreated esophageal varices; uncontrolled ascites;~* episodes of hepatic encephalopathy within the last 4 weeks;~* spinal cord compression; major surgery within 4 weeks prior to enrollment;~* radiation therapy within 2 weeks prior to enrollment;~* last anti-cancer treatment within 2 weeks prior to screening;~* previous high-dose chemotherapy requiring stem cell rescue;~* prior to irradiation to \>25% of the bone marrow;~* gastrointestinal abnormalities;~* known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet;~* clinically significant bacterial, fungal or viral infections for non-liver cancer patients;~* clinically significant cardiovascular disease;~* uncontrolled hypertension; acute pancreatitis with predisposing characteristics;~* history of grade 3 or 4 interstitial fibrosis or interstitial lung disease;~* active hemoelysis or evidence of biliary sepsis;~* prior major gastrointestinal surgery;~* concurrent use of known strong CYP3A inhibitors, inducers and P-gp substrates with a narrow therapeutic index;~* concurrent use of CYP3A substrates with narrow therapeutic indices;~* prior treatment with lorlatinib; active bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A1 Normal hepatic function (Type: ACTIVE_COMPARATOR): continued daily administration of lorlatinib in patients with normal hepatic function
- Group A2 Normal hepatic function (Type: ACTIVE_COMPARATOR): continued daily administration of lorlatinib in patients with normal hepatic function
- Group B mild hepatic impairment (Type: EXPERIMENTAL): continued daily administration of lorlatinib in patients with mild hepatic impairment
- Group C moderate hepatic impairment (Type: EXPERIMENTAL): continued daily administration of lorlatinib in patients with moderate hepatic impairment
- Group D severe hepatic impairment (Type: EXPERIMENTAL): continued daily administration of lorlatinib in patients with severe hepatic impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is informed of the investigational nature of this study and has given written, witnessed informed consent in accordance with institutional, local, and national guidelines~* Males or females ≥ 18 years of age. Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening; those who are sexually active must practice a highly effective method of birth control for at least 4 weeks prior to study drug administration, and must be willing to continue contraception until at least 4 weeks after the last dose of study drug.~* Participant who has received at least 24 weeks of peginesatide dosing in a previous Affymax-sponsored study~* One hemoglobin value of \> 10.0 g/dL in the 4 weeks prior to study drug administration~Exclusion Criteria:~* Known intolerance to peginesatide or pegylated products~* History of antibodies to any erythropoiesis stimulating agent (ESA) or history of pure red cell aplasia (PRCA)~* High likelihood of early withdrawal or interruption of the study (e.g., participant suffers from any clinically significant medical disease or condition that may, in the Investigator's opinion, interfere with safety, assessment, or follow-up of the participant)~* Anticipated life expectancy \< 18 months~* Receipt of any ESA other than peginesatide at any time after participant enrollment in the previous Affymax-sponsored study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age~   1. Phase I: Eighteen (18) years or older.~  2. Phase II: Seven (7) years or older.~2. Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB)~Key Exclusion Criteria:~1. Medical instability limiting ability to travel to the investigative center.~2. Active infection with HIV, hepatitis B or hepatitis C or evidence of other systemic infection~3. Current evidence of metastatic squamous cell carcinoma at the site to be injected~4. Clinically significant abnormal laboratory result or other significant clinical abnormalities~5. Receipt of a chemical or biological study product for the specific treatment of RDEB in the past six months

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FCX-007 (Type: EXPERIMENTAL): In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.~All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-50 years of age~* Women ≥ 24 weeks viable gestation~* Will be undergoing cesarean delivery~Exclusion Criteria:~* Patient unwilling or unable to provide consent.~* No or very limited prenatal care or a non-resident patient who is unlikely to follow-up after delivery.~* Immunosuppressed subjects: i.e., taking systemic immunosuppressant or steroids (e.g. transplant subjects; not including steroids for lung maturity), HIV with CD4 \<200, or other~* Decision not to have skin closure (e.g. secondary wound closure, mesh closure)~* Current skin infection~* Coagulopathy~* High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, tubal ligation, bowel or adnexal surgery)~* Incarcerated individuals~* Intraamniotic infection~* Subjects participating on other treatment trials or studies that would interfere with the current study's primary outcome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Suture wound closure (Type: ACTIVE_COMPARATOR): Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.
- Absorbable staple wound closure (Type: EXPERIMENTAL): Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with advanced histologically confirmed biliary cancer (gallbladder cancer or cholangiocarcinoma) that is not amenable to conventional surgical approach~* 18 years or older~* Life expectancy of at least 12 weeks~* Eastern Cooperative Oncology Group (ECOG) Performance Status score less than 3~* Willing and able to sign informed consent~* Sexually active men and women must use an accepted and effective method of contraception (including barrier contraception with spermicide)~* Women of child-bearing age must have a negative pregnancy test~* Laboratory criteria~Exclusion Criteria:~* Prior chemotherapy (excluding chemotherapy given as adjuvant treatment completing more than 6 months prior to entry into study)~* Unstable angina, or class III or IV New York Heart Association heart disease~* Central nervous system metastases~* Uncontrolled diabetes mellitus~* Uncontrolled seizure disorder~* Major surgery, chemotherapy, immunotherapy, or radiotherapy during the 28 days preceding the first study treatment~* Need for concomitant anticancer therapy (chemotherapy, immunotherapy, or radiation) or other investigational agents during study participation or 28 days prior to study participation~* Pregnant or breast-feeding~* A known history of human immunodeficiency virus (HIV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- becatecarin (Type: EXPERIMENTAL): becatecarin
- 5-FU Plus Leucovorin (LV) (Type: ACTIVE_COMPARATOR): 5-Fluorouracil (5-FU) Plus Leucovorin (LV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy